Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amryt Pharma Plc ADR (NQ: AMYT ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 11, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Amryt Pharma Plc ADR < Previous 1 2 3 Next > Top 5 Health Care Stocks That Are Ticking Portfolio Bombs March 14, 2023 The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 January 18, 2023 Via Benzinga Why Shares of Amryt Pharma Jumped This Week January 12, 2023 A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares. Via The Motley Fool Recap: Amryt Pharma Q3 Earnings November 03, 2022 Amryt Pharma (NASDAQ:AMYT) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Filsuvez's European Approval Adds Growth Driver For Amryt Pharma June 24, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023 January 10, 2023 Via Benzinga Recap: Amryt Pharma Q1 Earnings May 04, 2022 Amryt Pharma (NASDAQ:AMYT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease April 22, 2022 Via Benzinga S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher January 09, 2023 U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Monday. Via Benzinga Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session January 09, 2023 Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. Via Benzinga Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients April 13, 2022 Amryt Pharma Plc (NASDAQ: AMYT) has Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session January 09, 2023 Via Benzinga Nasdaq Surges Over 200 Points; Crude Oil Rises 2% January 09, 2023 U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday. Via Benzinga Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday January 09, 2023 U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. Via Benzinga US Stocks Open Higher; Dow Rises 150 Points January 09, 2023 U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 9, 2023 January 09, 2023 Via Benzinga Adobe To Rally 25%? Here Are 10 Other Analyst Forecasts For Monday January 09, 2023 Via Benzinga Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B January 09, 2023 Italian family-controlled global pharmaceutical company Chiesi Farmaceutici S.p.A. has agreed to acquire Amryt Pharma Plc (NASDAQ: AMYT) for an implied value of $1.25 billion in upfront consideration. Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session January 09, 2023 Via Benzinga Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket January 09, 2023 Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday January 09, 2023 We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! Via InvestorPlace Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary September 08, 2022 Via Benzinga Amryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder Candidate September 08, 2022 The Medical Healthcare & Products Regulatory Agency (MHRA) has granted Marketing Authorisation Approval (MAA) and Orphan Disease Designation (ODD) for Amryt’s (NASDAQ: AMYT) lead candidate Filsuvez for... Via Benzinga The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures July 14, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session July 14, 2022 Via Benzinga Amryt Shares Shoot Higher As FDA Grants Orphan Drug Status To Carcinoid Tumor Candidate July 14, 2022 The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Amryt’s (NASDAQ: AMYT) lead drug Mycapssa for the treatment of carcinoid syndrome. Carcinoid syndrome (CS) is the most... Via Benzinga The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise June 23, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 23, 2022 Via Benzinga 55 Biggest Movers From Friday April 25, 2022 Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate... Via Benzinga Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus March 09, 2022 Amryt Pharma Plc's (NASDAQ: AMYT) Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million. The growth was driven by metreleptin... Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
